- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01786655
Safety Study of Long-Acting Local Anesthetic
Neosaxitoxin (NeoSTX) Alone and in Combination With Bupivacaine as Prolonged Duration Local Anesthetics: A Phase I Investigator-initiated Dose Escalation Study
The primary aim of this Phase 1 study is to evaluate the systemic safety of a novel prolonged-duration local anesthetic, Neosaxitoxin (NeoSTX), given by subcutaneous injection in combination with the commonly used local anesthetic, bupivacaine, and epinephrine.
The investigators hypothesize that a "minimal adverse effect threshold" NeoSTX dose for subcutaneous administration in combination with bupivacaine 0.2% and epinephrine 5mcg/ml respectively, can be defined for awake, young adult healthy volunteer subjects. At the same time, the pharmacokinetics of NeoSTX when delivered subcutaneously will be determined.
Study Overview
Status
Conditions
Detailed Description
Currently available amino amide local anesthetics (e.g. bupivacaine, levobupivacaine, ropivacaine) do not reliably provide analgesia beyond roughly 8 hours following subcutaneous infiltration. In addition, they can cause systemic toxicities such as seizures, arrhythmias, and cardiac arrest, as well as local tissue toxicities to muscle, cartilage and nerve. Therefore, there is a need for safe local anesthetics that can provide longer duration analgesia with low systemic and local tissue toxicities.
The investigator team previously reported that tetrodotoxin, saxitoxin, and NeoSTX could produce prolonged sensory blockade (numbness) and motor blockade (weakness) following injection near the sciatic nerves in rats. In these studies, combining the site 1 toxin with either bupivacaine or epinephrine dramatically improved efficacy (duration of sensory blockade) and reduced systemic toxicity.
NeoSTX is the most potent member of the STX series identified to date. In preliminary studies, investigators at the University of Chile, Santiago, and with a small biotech company, Proteus S.A, developed a bioreactor process to produce clinical grade NeoSTX efficiently, with excellent purity, stability, sterility and non-pyrogenicity. A series of preclinical safety and toxicologic studies in mice, rats, and sheep were performed at CHB and Toxikon, Inc.
In this proposal, the investigators plan to conduct a Phase I study to be performed under an Investigator-Initiated FDA IND to further establish the systemic and local safety of escalating doses of NeoSTX via sub-cutaneous infiltration in healthy and awake young adult male human volunteer subjects.
The primary aim of this Phase 1 study is to evaluate the systemic safety of a novel prolonged-duration local anesthetic, neosaxitoxin (NeoSTX), given by subcutaneous injection, either alone or in combination with the commonly used local anesthetic, bupivacaine, and epinephrine. The hypothesis is that, using adverse events as endpoints, a "minimal adverse effect threshold" NeoSTX dose for subcutaneous administration in combination with bupivacaine 0.2% and epinephrine 5mcg/ml respectively, can be defined for awake, young adult healthy volunteer subjects.
In double blind fashion, each subject will receive two injections simultaneously in a 3 cm x 3cm square area on skin of the posterior aspect of the lower leg (calf), one on each side. Each subject receives one injection with bupivacaine 0.2% alone on one side. On other side, they will receive one of 4 possible solutions: (1) saline placebo, (2) NeoSTX in saline or (3) NeoSTX in combination with bupivacaine or (4) NeoSTX in combination with bupivacaine 0.2% and epinephrine 5mcg/ml.
In each dose group, only one of the injections involves placebo. Prior to each dose increase, there is a safety review and confirmation that no stopping rule has been reached.
Specific Aims
- Measure the dose dependence of FDA-AEs and SD-AEs from NeoSTX in saline;
- Measure the dose dependence of FDA-AEs and SD-AEs from NeoSTX in bupivacaine 0.2%;
- Measure the dose dependence of FDA-AEs and SD-AEs from NeoSTX in bupivacaine 0.2% with epinephrine 5mcg/ml;
- Measure the serum and urine concentrations of NeoSTX following injections of NeoSTX alone or with bupivacaine 0.2% with and without epinephrine; and correlate the serum concentrations with the "Systemic Effects";
- Evaluate skin integrity and other potential local reactions (edema, numbness, and paresthesia, erythema) in treated limbs receiving NeoSTX-saline, NeoSTX-bupivacaine, NeoSTX-bupivacaine-epinephrine or plain bupivacaine.
- Using QST, establish the dependence of sensory blockade intensity and duration on NeoSTX dose and on presence or absence of bupivacaine and epinephrine;
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Boston Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adult males ages 18-35
- ASA physical status 1 or 2
- English or Spanish speakers
- Must be able to come to Boston Children's Hospital for a 24-hour stay and able and willing to attend 5-10 study visits
- Must be able to provide informed consent
- Must be able to understand and perform all the procedures of the study including self-reporting of symptom scores
Exclusion Criteria:
- ASA physical status 3 or greater
- Cognitively challenged or other inability to understand the self-report measures or to give informed consent
- Significant cardiovascular, respiratory, neuromuscular disease or other systemic illness(es)
- No known or suspected allergies to neosaxitoxin, bupivacaine, or other local anesthetics
- Subjects may not be on any pain controlling medications, or any medications that would alter pain tolerance
- Subjects may not be on any medication that would alter cognition
- Subjects may not have any acute or chronic pain conditions requiring ongoing treatment or limiting daily activities
- No alcohol or illicit drug abuse
- No current smokers
Study Plan
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Neosaxitoxin in saline
Subjects receive only one injection of NeoSTX in saline on the back of one calf (test side).
Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5mcg, 10mcg, 15mcg, 20mcg, 30mcg, and 40mcg NeoSTX.
|
NeoSTX will be administered in sequential dose cohorts.
Each subject receives one injection with bupivacaine 0.2% alone on one side (control).
On the other side they receive NeoSTX in saline (test).
Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
|
EXPERIMENTAL: Neosaxitoxin + bupivacaine 0.2%
Subjects receive only one injection of NeoSTX in combination with 0.2% bupivacaine on the back of one calf (test side).
Subjects receive NeoSTX in bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg NeoSTX.
|
NeoSTX will be administered in sequential dose cohorts.
Each subject receives one injection with bupivacaine 0.2% on one side (control).
On the other side they receive NeoSTX with 0.2% bupivacaine.
Subjects receive NeoSTX in 0.2% bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
|
EXPERIMENTAL: Neosaxitoxin + bupivacaine 0.2% + epinephrine 5mcg/ml
Subjects receive one injection of NeoSTX in bupivacaine 0.2% with epinephrine 5 mcg/ml on the back of one calf (test side).
Subjects receive NeoSTX in bupivacaine 0.2% with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
|
Each subject receives one injection with bupivacaine 0.2% on one side (control).
On the other side they receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml.
Subjects receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
|
PLACEBO_COMPARATOR: Saline placebo
Subjects receive one injection of saline on the back of one calf (test side).
|
Each subject receives one injection with bupivacaine 0.2% alone on one side.
On the other side they receive saline placebo.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Presence or absence of Adverse Events as a function of NeoSTX dose
Time Frame: Within 14 days of injection
|
Within 14 days of injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic parameters characterizing uptake and distribution of NeoSTX (content in serum and urine samples)
Time Frame: Within 24 hours of injection
|
Within 24 hours of injection
|
|
Cutaneous sensory blockade (numbness)
Time Frame: Within 14 days of injection
|
measured by noninvasive quantitative sensory testing (QST)
|
Within 14 days of injection
|
Local skin reactions (edema, paresthesias and urticaria)
Time Frame: Within 14 days of injection
|
Within 14 days of injection
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Anesthetics, Local
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Neuromuscular Agents
- Adrenergic beta-Agonists
- Sympathomimetics
- Vasoconstrictor Agents
- Mydriatics
- Neuromuscular Blocking Agents
- Bupivacaine
- Epinephrine
- Neosaxitoxin
Other Study ID Numbers
- IRB-P00003344
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Safety of Neosaxitoxin in Healthy Volunteers
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Safety and Tolerability in ElderlyUnited States
-
Xencor, Inc.ICON Clinical ResearchCompletedSafety in Healthy VolunteersUnited States
-
Veralox TherapeuticsCompletedSafety and Tolerability in Healthy VolunteersUnited States
-
MingSight Pharmaceuticals Pty LimitedCompletedSafety and PK in Healthy VolunteersAustralia
-
Annexon, Inc.TerminatedSafety and Tolerability in Healthy VolunteersAustralia
-
Neuraly, Inc.CompletedSafety and Tolerability in Healthy VolunteersUnited States
-
Annexon, Inc.Nucleus Network LtdCompletedSafety and Tolerability in Healthy VolunteersAustralia
-
LG ChemCompletedBioavailability, Safety and Tolerability Among Different Eutropin Formulations in Healthy VolunteersKorea, Republic of
-
TheracosCompletedSafety and Tolerability of EGT0001474 in Healthy VolunteersUnited States
-
ARC Medical Devices Inc.Completed
Clinical Trials on Neosaxitoxin in saline
-
Grünenthal GmbHTerminatedAnalgesia | Anesthesia, Local | AnesthesiaNetherlands
-
McGill University Health Centre/Research Institute...CompletedSepsis | Gastroenteritis | Urinary Tract Infection | BronchiolitisCanada
-
Instituto Tecnologico y de Estudios Superiores...Tecnologico de MonterreyCompleted
-
Boston Children's HospitalAbbottCompletedGastroenteritis | DehydrationUnited States
-
Ornge Transport MedicineWithdrawnBarotrauma | Injury of Trachea | Friction and Pressure Injuries | Transfer/Transport InjuryCanada
-
State University of New York - Upstate Medical...CompletedChronic Migraine, HeadacheUnited States
-
Children's Hospital of PhiladelphiaAmerican Academy of Pediatrics; Academic Pediatric AssociationCompleted
-
Bastyr UniversityNational Center for Complementary and Integrative Health (NCCIH)Completed
-
Ain Shams UniversityUnknown
-
All India Institute of Medical Sciences, New DelhiCompleted